Analysts expect Invacare Co. (NYSE: IVC) to post earnings of $ 0.02 per share for the current quarter, according to Zacks Investment Research. Two analysts have estimated Invacare’s revenue, with estimates ranging from ($ 0.01) to $ 0.05. Invacare posted earnings of ($ 0.10) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 120%. The company is expected to release its next quarterly results on Wednesday, February 9.

On average, analysts expect Invacare to report annual earnings of ($ 0.73) per share for the current year, with EPS estimates ranging from 0.76 ($ 0.76) to ($ 0.70). For the next fiscal year, analysts expect the company to report earnings of ($ 0.24) per share, with EPS estimates ranging from ($ 0.39) to ($ 0.08). Zacks’ EPS averages are an average based on a survey of seller-side research analysts who follow Invacare.

Invacare (NYSE: IVC) last released its quarterly earnings data on Wednesday, October 27. The healthcare provider reported ($ 0.12) earnings per share for the quarter, beating analyst consensus estimates of ($ 0.20) by $ 0.08. Invacare recorded a negative return on equity of 10.50% and a negative net margin of 6.05%. The company posted revenue of $ 224.20 million in the quarter, compared to analysts’ estimates of $ 222.27 million. In the same quarter of last year, the company made EPS ($ 0.10).

IVC has been the subject of several recent analyst reports. Oppenheimer reduced its target price on Invacare from $ 11.00 to $ 9.00 and established an “outperform” rating on the stock in a Friday October 29th research note. Zacks Investment Research upgraded Invacare from a “sell” rating to a “custody” rating in a Tuesday, November 9th research note.

NYSE: IVC traded down $ 0.04 during Friday trading hours, reaching $ 2.73. 395,153 shares of the stock were traded, for an average volume of 1,084,772. The stock has a market cap of $ 95.60 million, a P / E ratio of -1.80 and a beta of 1.04 . Invacare has a 52-week low of $ 2.18 and a 52-week high of $ 10.94. The company has a quick ratio of 0.98, a current ratio of 1.64, and a debt ratio of 1.55. The company has a 50-day simple moving average of $ 3.18 and a 200-day simple moving average of $ 5.49.

Hedge funds and other institutional investors recently changed their holdings of stocks. Metropolitan Life Insurance Co NY purchased a new position in Invacare shares during the first quarter valued at $ 102,000. Victory Capital Management Inc. strengthened its position in Invacare by 32.8% during the second quarter. Victory Capital Management Inc. now owns 189,500 shares of the healthcare provider valued at $ 1,529,000 after purchasing an additional 46,797 shares in the last quarter. Citigroup Inc. strengthened its position in Invacare by 410.2% in the second quarter. Citigroup Inc. now owns 18,682 shares of the healthcare provider valued at $ 151,000 after purchasing an additional 15,020 shares in the last quarter. Principal Financial Group Inc. strengthened its position in Invacare by 7.8% in the second quarter. Principal Financial Group Inc. now owns 283,807 shares of the healthcare provider valued at $ 2,290,000 after purchasing an additional 20,438 shares in the last quarter. Finally, Brandes Investment Partners LP strengthened its position in Invacare by 32.3% during the second quarter. Brandes Investment Partners LP now owns 17,593 shares of the healthcare provider valued at $ 142,000 after purchasing an additional 4,294 shares in the last quarter. Institutional investors and hedge funds hold 97.96% of the company’s shares.

Invacare Company Profile

Invacare Corp. is engaged in the manufacture and distribution of medical equipment used in non-acute care facilities. He focuses on medical device solutions for congenital, acquired and degenerative diseases. The company operates in the following segments: North America and Europe. The company was founded by Aaron Malachi Mixon III in 1979 and is headquartered in Elyria, OH.

Read more: Buy-Side Analysts

Get a Free Copy of Zacks’ Research Report on Invacare (IVC)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in Invacare now?

Before you consider Invacare, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold ... and Invacare was not on the list.

While Invacare currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here